

(51) International Patent Classification:
A61K 41/00 (2020.01)(21) International Application Number:
PCT/US2021/032078(22) International Filing Date:
12 May 2021 (12.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/023,635	12 May 2020 (12.05.2020)	US
63/078,747	15 September 2020 (15.09.2020)	US
63/114,990	17 November 2020 (17.11.2020)	US
63/131,698	29 December 2020 (29.12.2020)	US
63/136,156	11 January 2021 (11.01.2021)	US

(71) Applicant: **IGM BIOSCIENCES, INC.** [US/US]; 325 East Middlefield Road, Mountain View, California 94043 (US).

(72) Inventors: **WANG, Beatrice**; IGM Biosciences, Inc., 325 East Middlefield Road, Mountain View, California 94043 (US). **MATTHEW, Thomas J.**; IGM Biosciences, Inc., 325 East Middlefield Road, Mountain View, California 94043 (US). **HUMKE, Eric William**; IGM Biosciences, Inc., 325 East Middlefield Road, Mountain View, California 94043 (US). **SINCLAIR, Angus**; IGM Biosciences, Inc., 325 East Middlefield Road, Mountain View, California 94043 (US). **CHEN, Daniel S.**; IGM Biosciences, Inc., 325 East Middlefield Road, Mountain View, California 94043 (US).

(US). **KEYT, Bruce Alan**; IGM Biosciences, Inc., 325 East Middlefield Road, Mountain View, California 94043 (US). **WANG, Ling**; IGM Biosciences, Inc., 325 East Middlefield Road, Mountain View, California 94043 (US).

(74) Agent: **JARECKI, Jessica L.** et al.; IGM Biosciences, Inc., 325 East Middlefield Road, Mountain View, California 94043 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CANCER THERAPY FOR TREATING CANCER




FIG. 7A

(57) Abstract: This disclosure provides therapeutic methods for treating cancer including combination therapy with a multimeric anti-DR5 antibody and a cancer therapy, e.g., radiation, an anthracycline, a folic acid analog, a platinum-based agent, a taxane, a topoisomerase II inhibitor, a SMAC mimetic, a vinca alkaloid, a Bruton's tyrosine kinase (BTK) inhibitor, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, a myeloid cell leukemia-1 (Mcl-1) inhibitor, or any combination thereof.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*